<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02393248</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 54828-101</org_study_id>
    <nct_id>NCT02393248</nct_id>
  </id_info>
  <brief_title>Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)</brief_title>
  <official_title>A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study will be to evaluate the safety, tolerability, and pharmacological&#xD;
      activity of pemigatinib in subjects with advanced malignancies. This study will have three&#xD;
      parts, dose escalation (Part 1), dose expansion (Part 2) and combination therapy (Part 3).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 27, 2015</start_date>
  <completion_date type="Anticipated">November 24, 2021</completion_date>
  <primary_completion_date type="Actual">December 14, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the maximum tolerated dose of Pemigatinib as a monotherapy and in combination as measured by the number of participants with adverse events</measure>
    <time_frame>from baseline through 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the pharmacodynamics of pemigatinib as a monotherapy and in combination as indicated by serum phosphorus level</measure>
    <time_frame>up to 30 days (+ 5 days) follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Preliminary efficacy as assessed by Overall Response Rate (ORR) of Pemigatinib as monotherapy and in combination in subjects with measurable disease</measure>
    <time_frame>Day 15 of every third cycle (Â± 2 days) while subjects are on study</time_frame>
    <description>Tumor response rates in those subjects with measurable disease as determined by investigator assessment of response using RECIST (Response Evaluation Criteria in Solid Tumor) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) during the dosing interval and Cmin of Pemigatinib as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The pharmacokinetic (PK) parameters of Cmax and Cmin will be calculated from the blood plasma concentrations of pemigatinib using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum observed plasma concentration (Cmin) during the dosing interval of Pemigatinib as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The pharmacokinetic (PK) parameters of Cmax and Cmin will be calculated from the blood plasma concentrations of pemigatinib using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) of Pemigatinib as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The PK parameter of Tmax will be calculated from the blood plasma concentrations of pemigatinib using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the single-dose plasma concentration-time curve (AUC0-t) of Pemigatinib as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>Area under the single-dose plasma concentration-time curve from Hour 0 to the last quantifiable measurable plasma concentration, calculated by the linear trapezoidal rule for increasing concentrations and the log trapezoidal rule for decreasing concentrations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral dose clearance (Cl/F) of Pemigatinib as monotherapy and in combination</measure>
    <time_frame>Cycle 1 Day 1, Day 2, Day 8 and Day 15</time_frame>
    <description>The PK parameter of Cl/F will be calculated from the blood plasma concentrations of pemigatinib using standard noncompartmental PK methods.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Solid Tumor</condition>
  <condition>Gastric Cancer</condition>
  <condition>Urothelial Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myeloproliferative Neoplasms</condition>
  <condition>Breast Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>UC</condition>
  <condition>MPN</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Open-label dose escalation with an accelerated titration design based on observing each dose level for a period of 21 days.&#xD;
Dose Expansion&#xD;
Combination therapy:&#xD;
Gemcitabine + Cisplatin + Pemigatinib&#xD;
Pembrolizumab + Pemigatinib&#xD;
Docetaxel + Pemigatinib&#xD;
Trastuzumab + Pemigatinib&#xD;
INCMGA00012 + Pemigatinib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemigatinib</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
    <other_name>INCB054828</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine + Cisplatin</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INCMGA00012</intervention_name>
    <arm_group_label>Dose Escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female subjects, age 18 years or older on day of signing consent&#xD;
&#xD;
          2. Part 1: Any advanced solid tumor malignancy; Part 2: Subjects with squamous non-small&#xD;
             cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer,&#xD;
             breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy&#xD;
             that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR&#xD;
             genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor receptor&#xD;
             (FGFR) alteration may be based on local or central laboratory results. Part 3: Dose&#xD;
             finding: subjects with solid tumor malignancies who qualify for combo therapy;&#xD;
             dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy&#xD;
&#xD;
          3. Has progressed after prior therapy and there is no further effective standard&#xD;
             anticancer therapy available (including subject refuses or is intolerant)&#xD;
&#xD;
          4. Life expectancy &gt; 12 weeks&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group (ECOG) performance status:&#xD;
&#xD;
               -  Part 1: 0 or 1&#xD;
&#xD;
               -  Part 2 and 3: 0, 1, or 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with other investigational study drug for any indication for any reason, or&#xD;
             receipt of anticancer medications within 21 days or 5 half-lives before first dose of&#xD;
             study drug&#xD;
&#xD;
          2. Prior receipt of a selective FGFR inhibitor&#xD;
&#xD;
          3. History of a calcium/phosphate homeostasis disorder&#xD;
&#xD;
          4. History and/or current evidence of ectopic mineralization/calcification&#xD;
&#xD;
          5. Current evidence of corneal disorder/keratopathy&#xD;
&#xD;
          6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac&#xD;
             function parameters outside protocol-defined range&#xD;
&#xD;
          7. Prior radiotherapy within 2 weeks of study treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luis FÃ©liz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Incyte Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama At Birmingham Comprehensive Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>West Hollywood</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of the Tr</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University - Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center, Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health - Monter Cancer Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University - Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signal Point Clinical Research Center</name>
      <address>
        <city>Middletown</city>
        <state>Ohio</state>
        <zip>45042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System Cancer Institute</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Ctr</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Md Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Health</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Finsen Centre National Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>02100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2015</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alterations in FGF or FGFR</keyword>
  <keyword>squamous non-small cell lung cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>urothelial cancer</keyword>
  <keyword>endometrial cancer</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>MPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

